NCT03220477 2025-08-06Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Memorial Sloan Kettering Cancer CenterPhase 1 Active not recruiting28 enrolled